Skip to Content
Merck
All Photos(1)

Documents

Safety Information

SML0356

Sigma-Aldrich

Etonogestrel

≥98% (HPLC)

Synonym(s):

(17α)-13-Ethyl-17-hydroxy-11-methylene-18,19-dinorpregn-4-en-20-yn-3-one, 3-Keto-desogestrel, 3-Oxo-desogestrel

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C22H28O2
CAS Number:
54048-10-1
Molecular Weight:
324.46
EC Number:
258-936-2
MDL number:
MFCD00867863
UNSPSC Code:
51111800
PubChem Substance ID:
329825358
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +80 to +95°, c = 1 (CHCl3)

color

white to beige

solubility

DMSO: >5 mg/mL

storage temp.

−20°C

SMILES string

CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C

InChI

1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1

InChI key

GCKFUYQCUCGESZ-BPIQYHPVSA-N

Gene Information

human ... PGR(5241)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Etonogestrel is a lipophilic molecule. Pharmacokinetics studies reveal that etonogestrel is bound to protein albumin in the blood. This remains independent of both endogenous and exogenous concentration of estradiol.
Etonogestrel is a third-generation progestin contraceptive. Etonogestrel is used as a contraceptive itself and is also the active metabolite of the drug desogestrel used in some combination contraceptives.

Features and Benefits

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H351,H360

Precautionary Statements

P201 - P308 + P313

Hazard Classifications

Carc. 2 - Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

SML0356-VAR:
SML0356-BULK:
SML0356-25MG:
SML0356-5MG:

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 2

1 of 2

Ethinyl Estradiol Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1480

Ethinyl Estradiol

17α-Ethynylestradiol ≥98%

Sigma-Aldrich

E4876

17α-Ethynylestradiol

Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon
Wenzl R, et al.
Contraception, 58(5), 283-288 (1998)
Peter Schnabel et al.
Clinical drug investigation, 32(6), 413-422 (2012-05-01)
The etonogestrel (ENG)-releasing implant is a subdermal progestogen-only contraceptive that provides coverage for up to 3 years. This long-acting hormonal contraceptive has been available in Europe since 1998 and in the US since 2006. To date, localization of non-palpable implants
Kristina M Tocce et al.
American journal of obstetrics and gynecology, 206(6), 481-481 (2012-05-29)
The purpose of this study was to determine contraceptive continuation and repeat pregnancy rates in adolescents who are offered immediate postpartum etonogestrel implant (IPI) insertion. Participants in an adolescent prenatal-postnatal program were enrolled in a prospective observational study of IPI
Diana Mansour et al.
Contraception, 83(3), 202-210 (2011-02-12)
The aim of this guidance is to review the management of unacceptable vaginal bleeding patterns in etonogestrel (ENG)-releasing contraceptive implant users concentrating, where possible, on the evidence for pharmacological treatments and identifying a pragmatic approach where this is not possible.
Anne Calhoun et al.
Headache, 52(8), 1246-1253 (2012-07-14)
To determine whether extended-cycle dosing of an ultralow dose vaginal ring contraceptive decreases frequency of migraine aura and prevents menstrual related migraine (MRM). Many women are denied therapy with combined hormonal contraceptives due to published guidelines that recommend against their
View All Related Papers

Articles

nuclear-receptors-steroids

We offers many products related to Nuclear Receptors (Steroids) for your research needs.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service